Related Experiment Video
Updated: Mar 22, 2026

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
A combination of scGOS/lcFOS with Bifidobacterium breve M-16V protects suckling rats from rotavirus gastroenteritis
M Rigo-Adrover1,2, S Saldaña-Ruíz1,2, K van Limpt3
1Department of Physiology, Faculty of Pharmacy, University of Barcelona, Av. Joan XXIII s/n, 08028, Barcelona, Spain.
Insights
A daily prebiotic and probiotic supplement effectively reduced rotavirus (RV) diarrhea in infant rats. Both interventions modulated immune responses and reduced viral shedding, offering a promising strategy for managing RV infections.
Area of Science:
- Gastroenterology
- Microbiology
- Immunology
Background:
- Rotavirus (RV) is a primary cause of severe infant diarrhea.
- Probiotics show potential against RV and other intestinal issues.
- Prebiotic effects on RV infection require further investigation.
Purpose of the Study:
- To evaluate the protective effects of a specific prebiotic mixture (scGOS/lcFOS 9:1), Bifidobacterium breve M-16V (probiotic), and their combination (synbiotic) in a rat model of RV infection.
Main Methods:
- Suckling rats received oral gavage of prebiotic, probiotic, or synbiotic from day 3 to 21.
- Rotavirus was administered on day 7.
- Clinical parameters and immune responses were assessed.
Main Results:
- Probiotic intervention decreased diarrhea incidence, severity, and duration.
- Prebiotic and synbiotic interventions also improved clinical parameters and significantly reduced viral shedding.
- All interventions modulated specific antibody responses in serum and intestinal washes.
Conclusions:
- Daily supplementation with the scGOS/lcFOS 9:1 prebiotic mixture, Bifidobacterium breve M-16V, or their combination is highly effective in mitigating RV-induced diarrhea in a preclinical model.
Purpose:
Rotavirus (RV) is the leading cause of severe diarrhoea among infants and young children, and although more standardized studies are needed, there is evidence that probiotics can help to fight against RV and other infectious and intestinal pathologies. On the other hand, the effects of prebiotics have not been properly addressed in the context of an RV infection. The aim of this study was to demonstrate a protective role for a specific scGOS/lcFOS 9:1 prebiotic mixture (PRE) separately, the probiotic Bifidobacterium breve M-16V (PRO) separately and the combination of the prebiotic mixture and the probiotic (synbiotic, SYN) in a suckling rat RV infection model.
Methods:
The animals received the intervention from the 3rd to the 21st day of life by oral gavage. On day 7, RV was orally administered. Clinical parameters and immune response were evaluated.
Results:
The intervention with the PRO reduced the incidence, severity and duration of the diarrhoea (p < 0.05). The PRE and SYN products improved clinical parameters as well, but a change in stool consistency induced by the PRE intervention hindered the observation of this effect. Both the PRE and the SYN, but not the PRO, significantly reduced viral shedding. All interventions modulated the specific antibody response in serum and intestinal washes at day 14 and 21 of life.
Conclusions:
A daily supplement of a scGOS/lcFOS 9:1 prebiotic mixture, Bifidobacterium breve M-16V or a combination of both is highly effective in modulating RV-induced diarrhoea in this preclinical model.
Related Concept Videos
Bacterial Gastroenteritis
Development of Human Microbiota
Development of the Oral Microbiota

